According to a WHO document discussing the safety of H1N1 vaccines, vaccine companies have deliberately released virus into the population via experimental vaccines:

‘In Europe, some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.’

Also, according to WHO, YOU AND YOUR FAMILY are the TEST subjects:

‘Time constraints mean that clinical data at the time when pandemic vaccines are first administered will inevitably be limited. Further testing of safety and effectiveness will need to take place after administration of the vaccine has begun.

For these reasons, WHO advises all countries administering pandemic vaccines to conduct intensive monitoring for safety and efficacy, and many countries have plans in place for doing so. On the positive side, mass vaccination campaigns can generate significant safety data within a few weeks.’

Source: http://www.who.int/csr/disease/swineflu/notes/h1n1_safety_vaccines_20090805/en/index.html

CDC Still Creating ‘Deadly’ Hybrid Viruses – Thanks a Lot, CDC!

Public-health officials are breathing a small sigh of relief that the H1N1 swine flu virus hasn’t mutated to become more deadly since emerging last spring. But what are the chances it will?

To find out, scientists at the CDC recently launched experiments in the agency’s labs in which they infected ferrets with both the new H1N1 virus and the highly lethal H5N1 avian flu virus to see if they might “reassort” to create a new hybrid.

The scientists want to know whether a combination of the H1N1 virus -– highly transmissible, but not terribly deadly -– and the H5N1 flu virus could create an easily transmissible, deadly scourge. The H5N1 virus has only sickened 440 people world-wide since 2003 and generally isn’t transmitted from one person to another. But it has killed 262, or about 60%, of those people, according to the World Health Organization.

The CDC scientists don’t have results of their lab experiments in ferrets yet, said Michael Shaw, associate director for laboratory science for the agency’s influenza division. While the experiments could produce viable combinations of the two viruses, the real question is whether any could create a virus that would spread, he said. “Viability is one thing,” he cautioned. “Whether it’s easily transmissible is another.”

Source: The Wall Street Journal, 17 September 2009.

H1N1 was Reassorted In A Lab

A virologist who has been researching the A/H1N1 virus has concluded after months of research that the ”novel” influenza was re-assorted in a laboratory from eight genes consisting of avian, swine and human type influenza A virus.

The scientist does not believe, based on intensive laboratory research of the A/H1N1 virus, that its sudden appearance in Mexico this past spring was a natural occurrence.

The reassortment of viruses occurs when one or more complete genes are exchanged enabling the virus to adapt to a new host. An example is when the avian virus switches gene with a human virus. In the case of A/H1N1, three genes were exchanged, from avian, swine, and human influenza viruses, resulting in the ressortant virus now expected to launch another deadly wave of infections in early October.

There are also signs that adaptation leading to mutation has occurred in the A/H1N1 strain. Several cases of mutated A/H1N1 have been reported from around the globe, rendering treatment with anti-A/H1N1 drugs and A/H1N1 vaccines ineffective.

The mutation of A/H1N1 has been discovered by our virologist source to have been more rapid than is naturally possible. The following is what was described in scientific terms about the rate of mutation of A/H1N1:

“Mutation takes time to occur, up to the rate of amino acid substitution. For example, for HA gene, or “duck virus,” HA has a substitution rate about 3 x 10e-4 per site per year which is slower compare to human and swine HA (about 10e-3 per site per year). If the total nucleotide number in influenza A virus HA is 1,700, then it takes three years for making a single change in the duck virus, or 1.7 year in the case of human and swine virus.”

The natural rate of mutation for a complete gene mutation, according to the virologist, takes “thousand of years to be established.”

As far as the reassortant A/H1N1 virus is concerned, there is a fear that a human was used as a laboratory “guinea pig” to permit the exchange of genes between humans, pigs, and fowl. The reasoning is that an individual was infected by avian, human and swine virus simultaneously, and the viruses exchanged genes inside the individual’s body, creating a new virus having mixed genes and then rapidly spreading to others.

Source: Online Journal, by Wayne Madsen, 16 September 2009.

Baxter Involved in More Criminal Activities

A company producing swine flu vaccine for Britain has paid millions of pounds in out-of-court settlements after being accused of fraudulently overcharging for medicines.

Baxter, the US pharmaceutical giant, reached at least seven huge settlements over the past 12 months, some of them for millions of dollars. The company had been accused of fraud amid allegations that it had overpriced medicines by as much as 1,300%.

The disclosure comes days after Baxter’s vaccine, Celvapan H1N1, was given approval by the European Medicines Agency and will raise fears about the growing costs of the swine flu pandemic. Vaccines are expected to cost the government £155m over the next four years.

Baxter became involved in prolonged litigation after being accused of fraudulently overcharging Medicaid, the US health programme that provides a safety net for the poorest families. Executives from the company paid out $2m to the Kentucky state government this year. Jack Conway, the Kentucky attorney general, said: “All of this could have been easily avoided if Baxter… had done what the law requires: report truthful prices.

“Taxpayers are footing the bill for these inflated drug prices, and my office is seeking to recover the money the Medicaid programme lost as a result of this deception and overpayment.”

Medicaid relies on published average wholesale prices (AWPs) to calculate the cost of medicines which pharmaceutical companies then provide at a reduced rate. But several US states have accused a series of pharmaceutical companies of grossly overinflating the AWPs. Seven other states have reached settlements with Baxter: Texas, Alabama, California, Hawaii, Alaska, Illinois and Wisconsin.

In May, Baxter was one of six pharmaceutical manufacturers that agreed to pay $89m to the state of Alabama. In February this year Baxter paid out $1.1m to Wisconsin. Three years ago the company agreed to pay out $8.5m to Texas.

Baxter was one of five companies that paid California state authorities $22.5m following accusations of Medicaid fraud, and the company also paid out $400,000 to Hawaii. In Alaska, Baxter agreed to pay compensation to settle a court claim. The company is also facing court action in Mississippi. Illinois has recovered $6.8m from Baxter, according to reports.

Despite the scandal, Baxter was one of two companies awarded the contract to produce 132 million doses of vaccine for Britain. The other company, GlaxoSmithKline, received a “positive opinion” for its drug, Pandemrix, last month. Britain is reported to have ordered enough swine flu vaccine to give each person two doses. The growing cost of the vaccines has prompted concerns from politicians, but the Department of Health and the drug companies have declined to say exactly how much each vaccine costs.

Source: The Guardian, 11 October 2009.